Volume 5, Issue 1 (Winter-Spring 2022)                   Mod Med Lab J 2022, 5(1): 14-25 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zangeneh Motlagh M, Tamimi A, Golroo R, Hossein-Khannazer N, Aminishakib P, Mahdavi N, et al . Oral squamous cell carcinoma, novel methods for early diagnosis and treatment. Mod Med Lab J. 2022; 5 (1) :14-25
URL: http://modernmedlab.com/article-1-109-en.html
Abstract:   (170 Views)
Oral squamous cell carcinoma (OSCC) represents the most common oral cavity cancer worldwide, being among the 10 most frequent cancers of all types. Only around 50% of patients survive longer than 5 years in view of currently applied medical procedures of diagnosis and treatment. The delay in diagnosis accounts for the shortening of survival despite advances in treatment protocols. The poor prognosis as well as high occurrence rate exerts a burden on both patients and clinicians. Cancer biomarkers may possibly present cancer profiles of different patients and foreseeing each upcoming therapy response and the subsequent outcomes. Identification of the most fundamental biomarkers in OSCC may lead us to precise detection, which can give rise to earlier diagnosis, more effective treatment options, and more patient oriented prognostic decisions, alleviating the current situation regarding the failure in effectual OSCC management.  In this review, we have outlined the molecular biomarkers for early diagnosis of OSCC and suggested inhibitors through which metastasis and its molecular pathways could potentially be inhibited.
 
Full-Text [PDF 916 kb]   (256 Downloads)    
Type of Study: Review | Subject: Immunology

References
1. Fact sheet of lip and oral cavity cancers. Global Cancer. 2020, March 30. [Article]
2. Estimated age-standardized incidence rates (World) in 2020, all cancers, both sexes, all ages. Global Cancer. 2020, March 30. [Article]
3. Cristaldi M, Mauceri R, Di Fede O, Giuliana G, Campisi G, Panzarella V. Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives. Front Physiol. 2019;10:1476. [DOI:10.3389/fphys.2019.01476]
4. Tampa M, Mitran MI, Mitran CI, Sarbu MI, Matei C, Nicolae I, et al. Mediators of Inflammation - A Potential Source of Biomarkers in Oral Squamous Cell Carcinoma. J Immunol Res. 2018;2018:1061780. [DOI:10.1155/2018/1061780]
5. Lindemann A, Takahashi H, Patel AA, Osman AA, Myers JN. Targeting the DNA Damage Response in OSCC with TP53 Mutations. Journal of Dental Research. 2018;97(6):635-44. [DOI:10.1177/0022034518759068]
6. Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett. 2014;8(1):7-11. [DOI:10.3892/ol.2014.2103]
7. Woods R, O'Regan EM, Kennedy S, Martin C, O'Leary JJ, Timon C. Role of human papillomavirus in oropharyngeal squamous cell carcinoma: A review. World J Clin Cases. 2014;2(6):172-93. [DOI:10.12998/wjcc.v2.i6.172]
8. Cancer causes (all infectious agents) among both sexes in 2018 attributable to infections, in the world, shown by infectious agents. Global Cancer. 2020, March 20. [Article]
9. Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA: a cancer journal for clinicians. 2015;65(5):401-21. [DOI:10.3322/caac.21293]
10. Giovannacci I, Vescovi P, Manfredi M, Meleti M. Non-invasive visual tools for diagnosis of oral cancer and dysplasia: A systematic review. Medicina oral, patologia oral y cirugia bucal. 2016;21(3):e305. [DOI:10.4317/medoral.20996]
11. Ferrari E, Pezzi ME, Cassi D, Pertinhez TA, Spisni A, Meleti M. Salivary Cytokines as Biomarkers for Oral Squamous Cell Carcinoma: A Systematic Review. International journal of molecular sciences. 2021;22(13):6795. [DOI:10.3390/ijms22136795]
12. Rivera C. Essentials of oral cancer. International journal of clinical and experimental pathology. 2015;8(9):11884. [Article]
13. Leemans CR, Snijders PJ, Brakenhoff RH. The molecular landscape of head and neck cancer. Nature Reviews Cancer. 2018;18(5):269-82. [DOI:10.1038/nrc.2018.11]
14. Kowalski L, Carvalho A. Natural history of untreated head and neck cancer. European Journal of Cancer. 2000;36(8):1032-7. [DOI:10.1016/S0959-8049(00)00054-X]
15. Almangush A, Bello IO, Coletta RD, Mäkitie AA, Mäkinen LK, Kauppila JH, et al. For early-stage oral tongue cancer, depth of invasion and worst pattern of invasion are the strongest pathological predictors for locoregional recurrence and mortality. Virchows Archiv. 2015;467(1):39-46. [DOI:10.1007/s00428-015-1758-z]
16. Almangush A, Heikkinen I, Mäkitie AA, Coletta RD, Läärä E, Leivo I, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis. British journal of cancer. 2017;117(6):856-66. [DOI:10.1038/bjc.2017.244]
17. Hoda SA, Cheng E. Robbins Basic Pathology. American Journal of Clinical Pathology. 2017;148(6):557. [DOI:10.1093/ajcp/aqx095]
18. Huss R, Guenther C, Hauser AJ. Advances in pharmaceutical cell therapy: principles of cell-based biopharmaceuticals: World Scientific; 2015. [Google Scholar]
19. Bigbee W, Herberman RB. Characteristics of the ideal tumor marker. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker. 2003. [Google Scholar]
20. Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z, et al. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC Cancer. 2018;18(1):911. [DOI:10.1186/s12885-018-4806-7]
21. Henry NL, Hayes DF. Cancer biomarkers. Molecular Oncology. 2012;6(2):140-6. [DOI:10.1016/j.molonc.2012.01.010]
22. Rivera C, Oliveira AK, Costa RAP, De Rossi T, Leme AFP. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral oncology. 2017;72:38-47. [DOI:10.1016/j.oraloncology.2017.07.003]
23. Poste G. Bring on the biomarkers. Nature. 2011;469(7329):156-7. [DOI:10.1038/469156a]
24. Bai Y, Sha J, Kanno T. The Role of Carcinogenesis-Related Biomarkers in the Wnt Pathway and Their Effects on Epithelial–Mesenchymal Transition (EMT) in Oral Squamous Cell Carcinoma. Cancers. 2020;12(3). [DOI:10.3390/cancers12030555]
25. Lakshminarayana S, Augustine D, Rao RS, Patil S, Awan KH, Venkatesiah SS, et al. Molecular pathways of oral cancer that predict prognosis and survival: A systematic review. J Carcinog. 2018;17:7. [DOI:10.4103/jcar.JCar_17_18]
26. Tojyo I, Shintani Y, Nakanishi T, Okamoto K, Hiraishi Y, Fujita S, et al. PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma. Maxillofac Plast Reconstr Surg. 2019;41(1):56. [DOI:10.1186/s40902-019-0239-8]
27. Lin LH, Chang KW, Kao SY, Cheng HW, Liu CJ. Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer. Int J Mol Sci. 2018;19(11). [DOI:10.3390/ijms19113303]
28. Pedro NF, Biselli JM, Maniglia JV, Santi-Neto D, Pavarino EC, Goloni-Bertollo EM, et al. Candidate Biomarkers for Oral Squamous Cell Carcinoma: Differential Expression of Oxidative Stress-Related Genes. Asian Pac J Cancer Prev. 2018;19(5):1343-9. [DOI:10.22034/APJCP.2018.19.5.1343]
29. Li G, Li X, Yang M, Xu L, Deng S, Ran L. Prediction of biomarkers of oral squamous cell carcinoma using microarray technology. Sci Rep. 2017;7:42105. [DOI:10.1038/srep42105]
30. Fadlullah MZ, Chiang IK, Dionne KR, San Yee P, Gan CP, Sam KK, et al. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. OncoTarget. 2016;7(19):27802. [DOI:10.18632/oncotarget.8533]
31. Sun J. RASSF-1A modulates proliferation-mediated oral squamous cell carcinoma progression. Cancer Cell Int. 2019;19(1):1-12. [DOI:10.1186/s12935-019-0932-9]
32. Omori H, Nishio M, Masuda M, Miyachi Y, Ueda F, Nakano T, et al. YAP1 is a potent driver of the onset and progression of oral squamous cell carcinoma. Science Advances. 2020; 6(12):eaay3324. [DOI:10.1126/sciadv.aay3324]
33. Ribeiro IP, Caramelo F, Marques F, Domingues A, Mesquita M, Barroso L, et al. WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. Cell Oncol (Dordr). 2016;39(6):573-82. [DOI:10.1007/s13402-016-0293-5]
34. Lima TB, Klein IP, Oliveira MG, Rados PV, Sant'Ana MF, Visioli F. Analysis of the Epithelium-Mesenchymal Transition Process on Oral Squamous Cell Carcinomas. Braz Dent J. 2017;28(5):543-7. [DOI:10.1590/0103-6440201701484]
35. Siriwardena S, Tsunematsu T, Qi G, Ishimaru N, Kudo Y. Invasion-Related Factors as Potential Diagnostic and Therapeutic Targets in Oral Squamous Cell Carcinoma-A Review. Int J Mol Sci. 2018;19(5):1462. [DOI:10.3390/ijms19051462]
36. Roche J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers (Basel). 2018;10(3):79. [DOI:10.3390/cancers10030079]
37. Xu Q, Zhang Q, Ishida Y, Hajjar S, Tang X, Shi H, et al. EGF induces epithelial-mesenchymal transition and cancer stem like cell properties in human oral cancer cells via promoting Warburg effect. OncoTarget. 2017;8(6):9557. [DOI:10.18632/oncotarget.13771]
38. Wang H, Liang X, Li M, Tao X, Tai S, Fan Z, et al. Chemokine (CC motif) ligand 18 upregulates Slug expression to promote stem-cell like features by activating the mammalian target of rapamycin pathway in oral squamous cell carcinoma. Cancer Sci. 2017;108(8):1584-93. [DOI:10.1111/cas.13289]
39. Wang H, Luo Q, Feng X, Zhang R, Li J, Chen F. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma. BMC Cancer. 2018;18(1):500. [DOI:10.1186/s12885-018-4403-9]
40. Huang WC, Jang TH, Tung SL, Yen TC, Chan SH, Wang LH. A novel miR-365-3p/EHF/keratin 16 axis promotes oral squamous cell carcinoma metastasis, cancer stemness and drug resistance via enhancing beta5-integrin/c-met signaling pathway. J Exp Clin Cancer Res. 2019;38(1):89. [DOI:10.1186/s13046-019-1091-5]
41. Sakata J, Hirosue A, Yoshida R, Kawahara K, Matsuoka Y, Yamamoto T, et al. HMGA2 Contributes to Distant Metastasis and Poor Prognosis by Promoting Angiogenesis in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences. 2019;20(10). [DOI:10.3390/ijms20102473]
42. Wang X, Wang C, Yan G, Kang Y, Sun G, Wang S, et al. BAP18 is involved in upregulation of CCND1/2 transcription to promote cell growth in oral squamous cell carcinoma. EBioMedicine. 2020;53:102685. [DOI:10.1016/j.ebiom.2020.102685]
43. Tang D, Tao D, Fang Y, Deng C, Xu Q, Zhou J. TNF-Alpha Promotes Invasion and Metastasis via NF-Kappa B Pathway in Oral Squamous Cell Carcinoma. Med Sci Monit Basic Res. 2017;23:141-9. [DOI:10.12659/MSMBR.903910]
44. Chen Z, Tao Q, Qiao B, Zhang L. Silencing of LINC01116 suppresses the development of oral squamous cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer Manag Res. 2019;11:6043-59. [DOI:10.2147/CMAR.S197583]
45. Lakshminarayana S, Augustine D, Rao RS, Patil S, Awan KH, Venkatesiah SS, et al. Molecular pathways of oral cancer that predict prognosis and survival: A systematic review. Journal of carcinogenesis. 2018;17. [DOI:10.4103/jcar.JCar_17_18]
46. Gadbail AR, Sarode SC, Chaudhary MS, Gondivkar SM, Tekade SA, Yuwanati M, et al. Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma. J Appl Oral Sci. 2021;29:e20200751. [DOI:10.1590/1678-7757-2020-0751]
47. Cutilli T, Leocata P, Dolo V, Altobelli E. p53 as a prognostic marker associated with the risk of mortality for oral squamous cell carcinoma. Oncol Lett. 2016;12(2):1046-50. [DOI:10.3892/ol.2016.4742]
48. de Vicente JC, Rodríguez-Santamarta T, Rodrigo JP, Blanco-Lorenzo V, Allonca E, García-Pedrero JM. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2019;28(3):546-54. [DOI:10.1158/1055-9965.EPI-18-0779]
49. Lotfi A, Mohammadi G, Tavassoli A, Mousaviagdas M, Chavoshi H, Saniee L. Serum levels of MMP9 and MMP2 in patients with oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2015;16(4):1327-30. [DOI:10.7314/APJCP.2015.16.4.1327]
50. Macha MA, Matta A, Sriram U, Thakkar A, Shukla NK, Datta Gupta S, et al. Clinical significance of TC21 overexpression in oral cancer. J Oral Pathol Med. 2010;39(6):477-85. [DOI:10.1111/j.1600-0714.2009.00854.x]
51. Cristaldi M, Mauceri R, Di Fede O, Giuliana G, Campisi G, Panzarella V. Salivary biomarkers for oral squamous cell carcinoma diagnosis and follow-up: current status and perspectives. Frontiers in physiology. 2019;10:1476. [DOI:10.3389/fphys.2019.01476]
52. Lin L-H, Chang K-W, Kao S-Y, Cheng H-W, Liu C-J. Increased plasma circulating cell-free DNA could be a potential marker for oral cancer. International Journal of Molecular Sciences. 2018;19(11):3303. [DOI:10.3390/ijms19113303]
53. Lee LT, Wong YK, Hsiao HY, Wang YW, Chan MY, Chang KW. Evaluation of saliva and plasma cytokine biomarkers in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018;47(6):699-707. [DOI:10.1016/j.ijom.2017.09.016]
54. Zhong L, Liu Y, Wang K, He Z, Gong Z, Zhao Z, et al. Biomarkers: paving stones on the road towards the personalized precision medicine for oral squamous cell carcinoma. BMC cancer. 2018;18(1):1-20. [DOI:10.1186/s12885-018-4806-7]
55. Siriwardena SB, Tsunematsu T, Qi G, Ishimaru N, Kudo Y. Invasion-related factors as potential diagnostic and therapeutic targets in oral squamous cell carcinoma—a review. International Journal of Molecular Sciences. 2018;19(5):1462. [DOI:10.3390/ijms19051462]
56. Khan W, Haragannavar VC, Rao RS, Prasad K, Sowmya SV, Augustine D, et al. P-Cadherin and WNT5A expression in assessment of lymph node metastasis in oral squamous cell carcinoma. Clin Oral Investig. 2022;26(1):259-73. [DOI:10.1007/s00784-021-03996-4]
57. Troeltzsch M, Künzel V, Haidari S, Troeltzsch M, Otto S, Ehrenfeld M, et al. Desmoglein-3 overexpression in oral squamous cell carcinoma is associated with metastasis formation and early recurrence: An immunohistochemical study. J Craniomaxillofac Surg. 2022; 50(3):281-8. [DOI:10.1016/j.jcms.2021.11.015]
58. Wang C, Liu X, Huang H, Ma H, Cai W, Hou J, et al. Deregulation of Snai2 is associated with metastasis and poor prognosis in tongue squamous cell carcinoma. International journal of cancer. 2012;130(10):2249-58. [DOI:10.1002/ijc.26226]
59. Bai Y, Sha J, Kanno T. The role of carcinogenesis-related biomarkers in the Wnt pathway and their effects on epithelial–mesenchymal transition (EMT) in oral squamous cell carcinoma. Cancers. 2020;12(3):555. [DOI:10.3390/cancers12030555]
60. Mao L, Zhuang R, Qin L, Han Z, Huang X, Chen R, et al. CCL18 overexpression predicts a worse prognosis in oral squamous cell carcinoma (OSCC). Neoplasma. 2020;67(3):700-6. [DOI:10.4149/neo_2020_190821N802]
61. Lu Z, Liang J, He Q, Wan Q, Hou J, Lian K, et al. The serum biomarker chemerin promotes tumorigenesis and metastasis in oral squamous cell carcinoma. Clin Sci (Lond). 2019;133(5):681-95. [DOI:10.1042/CS20181023]
62. Zhang H, Wang Z, Zhang Z. Hsa_circ_0009128 mediates progression of oral squamous cell carcinoma by influencing MMP9. Oral Dis. 2021. [DOI:10.1111/odi.14019]
63. Xu H, Yang Y, Zhao H, Yang X, Luo Y, Ren Y, et al. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol. 2016;37(1):447-53. [DOI:10.1007/s13277-015-3514-z]
64. Bourova-Flin E, Derakhshan S, Goudarzi A, Wang T, Vitte A-L, Chuffart F, et al. The combined detection of Amphiregulin, Cyclin A1 and DDX20/Gemin3 expression predicts aggressive forms of oral squamous cell carcinoma. British Journal of Cancer. 2021;125(8):1122-34. [DOI:10.1038/s41416-021-01491-x]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Modern Medical Laboratory Journal